These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559 [TBL] [Abstract][Full Text] [Related]
6. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151 [TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Schreiber S; Kämpgen E; Wagner E; Pirkhammer D; Trcka J; Korschan H; Lindemann A; Dorffner R; Kittler H; Kasteliz F; Küpcü Z; Sinski A; Zatloukal K; Buschle M; Schmidt W; Birnstiel M; Kempe RE; Voigt T; Weber HA; Pehamberger H; Mertelsmann R; Bröcker EB; Wolff K; Stingl G Hum Gene Ther; 1999 Apr; 10(6):983-93. PubMed ID: 10223732 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014 [TBL] [Abstract][Full Text] [Related]
11. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603 [TBL] [Abstract][Full Text] [Related]
12. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. Koster BD; Santegoets SJAM; Harting J; Baars A; van Ham SM; Scheper RJ; Hooijberg E; de Gruijl TD; van den Eertwegh AJM Cancer Immunol Immunother; 2019 Jun; 68(6):1025-1035. PubMed ID: 30852622 [TBL] [Abstract][Full Text] [Related]
13. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Dillman R; Barth N; Vandermolen L; Mahdavi K; Beutel L; de Leon C; DePriest C; Nayak S Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449 [TBL] [Abstract][Full Text] [Related]
14. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797 [TBL] [Abstract][Full Text] [Related]
15. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391 [TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507 [TBL] [Abstract][Full Text] [Related]
17. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. Gitlitz BJ; Belldegrun AS; Zisman A; Chao DH; Pantuck AJ; Hinkel A; Mulders P; Moldawer N; Tso CL; Figlin RA J Immunother; 2003; 26(5):412-9. PubMed ID: 12973030 [TBL] [Abstract][Full Text] [Related]
18. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Mahvi DM; Sondel PM; Yang NS; Albertini MR; Schiller JH; Hank J; Heiner J; Gan J; Swain W; Logrono R Hum Gene Ther; 1997 May; 8(7):875-91. PubMed ID: 9143914 [TBL] [Abstract][Full Text] [Related]
19. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Möller P; Sun Y; Dorbic T; Alijagic S; Makki A; Jurgovsky K; Schroff M; Henz BM; Wittig B; Schadendorf D Br J Cancer; 1998 Jun; 77(11):1907-16. PubMed ID: 9667667 [TBL] [Abstract][Full Text] [Related]
20. An Open-Label Study of the Safety and Efficacy of Tag-7 Gene-Modified Tumor Cells-Based Vaccine in Patients with Locally Advanced or Metastatic Malignant Melanoma or Renal Cell Cancer. Novik AV; Danilova AB; Sluzhev MI; Nehaeva TL; Larin SS; Girdyuk DV; Protsenko SA; Semenova AI; Danilov AO; Moiseyenko VM; Georgiev GP; Baldueva IA Oncologist; 2020 Sep; 25(9):e1303-e1317. PubMed ID: 32240562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]